Skip to main content
Year archive

Innovent Biologics, Inc. — 2025 filings

All 56 regulatory filings released by Innovent Biologics, Inc. (1801) in 2025, sourced directly from the official regulator.

56 Filings
2025 Period
2025 filings (56)
Filing Released Lang
VOLUNTARY ANNOUNCEMENT - TABOSUN (IPILIMUMAB N01 INJECTION) RECEIVED APPROVAL BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION, IN COMBINATION WITH SINTILIMAB AS NEOADJUVANT TREATMENT FOR COLO
Regulatory Filings
2025-12-29 English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF SEVEN INNOVATIVE DRUGS INCLUDING TYVYT NEW INDICATION AND SYCUME IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST
Regulatory Filings
2025-12-07 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2025-12-05 English
Next Day Disclosure Return
Share Issue/Capital Change
2025-12-05 English
CLOSING OF GLOBAL STRATEGIC PARTNERSHIP WITH TAKEDA AND ISSUANCE OF SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change
2025-12-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Share Issue/Capital Change
2025-12-03 English
VOLUNTARY ANNOUNCEMENT - PECONDLE (PICANKIBART INJECTION) RECEIVED APPROVAL FROM CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS
Regulatory Filings
2025-11-28 English
VOLUNTARY ANNOUNCEMENT - MAZDUTIDE 9MG SUPPLEMENTARY APPLICATION ACCEPTED FOR REVIEW BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings
2025-11-25 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings
2025-11-06 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE THIRD QUARTER OF 2025
Earnings Release Q3 2025
2025-10-30 English
GLOBAL STRATEGIC COLLABORATION WITH TAKEDA AND ISSUE OF SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change
2025-10-22 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings
2025-10-08 English
2025 INTERIM REPORT
Interim / Quarterly Report H1 2025
2025-09-29 English
VOLUNTARY ANNOUNCEMENT - MAZDUTIDE RECEIVED APPROVAL FROM CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
Regulatory Filings
2025-09-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Share Issue/Capital Change
2025-09-04 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2025-08-29 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025
Interim / Quarterly Report H2 2025
2025-08-27 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information
2025-08-26 English
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE
Board/Management Information
2025-08-26 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE SECOND QUARTER OF 2025
Earnings Release H1 2025
2025-08-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025
Share Issue/Capital Change
2025-08-06 English
DATE OF BOARD MEETING
Report Publication Announcement
2025-08-04 English
Next Day Disclosure Return
Share Issue/Capital Change
2025-07-04 English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change
2025-07-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
Regulatory Filings
2025-07-04 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2025-06-30 English
VOLUNTARY ANNOUNCEMENT - FIRST DUAL GCG/GLP-1 RECEPTOR AGONIST MAZDUTIDE RECEIVED APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR CHRONIC WEIGHT MANAGEMENT
Regulatory Filings
2025-06-27 English
PLACING OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change
2025-06-26 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-06-25 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
Share Issue/Capital Change
2025-06-05 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR SINTILIMAB COMBINATION WITH FRUQUINTINIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Regulatory Filings
2025-06-05 English
Form of Proxy for use at the Annual General Meeting to be held on Wednesday, June 25, 2025
Proxy Solicitation & Information Statement
2025-06-02 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2025-06-02 English
(1) PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS, (3) PROPOSED RE-APPOINTMENT OF THE EXTERNAL AUDITOR, (4) GRANT OF
Proxy Solicitation & Information Statement
2025-06-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
Share Issue/Capital Change
2025-05-08 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2025
Earnings Release Q1 2025
2025-05-01 English
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information
2025-04-29 English
2024 ANNUAL REPORT
Annual Report FY 2024
2025-04-29 English
VOLUNTARY ANNOUNCEMENT - THE THIRD-GENERATION EGFR TKI LIMERTINIB RECEIVED APPROVAL FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THE FIRST-LINE TREATMENT OF LUNG CANCER
Regulatory Filings
2025-04-25 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Regulatory Filings
2025-04-07 English
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE
Governance Information
2025-03-31 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information
2025-03-31 English
CHANGE IN COMPOSITION OF NOMINATION COMMITTEE AND DESIGNATION OF THE LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR
Board/Management Information
2025-03-31 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2025-03-28 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
Earnings Release FY 2024
2025-03-26 English
VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST IGF-1R MONOCLONAL ANTIBODY SYCUME RECEIVED APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THE TREATMENT OF THYROID EYE DISEASE
Regulatory Filings
2025-03-14 English
DATE OF BOARD MEETING
Report Publication Announcement
2025-03-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Regulatory Filings
2025-03-06 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTS THE NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW DESIGNATION TO IPILIMUMAB INJECTION IN COMBINATION WITH SINTILIMAB AS
Regulatory Filings
2025-02-24 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE YEAR AND THE FOURTH QUARTER OF 2024
Regulatory Filings
2025-02-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Share Issue/Capital Change
2025-02-06 English
VOLUNTARY ANNOUNCEMENT - THE THIRD-GENERATION EGFR TKI LIMERTINIB RECEIVED APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THE TREATMENT OF LUNG CANCER
Regulatory Filings
2025-01-17 English
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENT
Regulatory Filings
2025-01-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
Share Issue/Capital Change
2025-01-07 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES SECOND NEW DRUG APPLICATION OF ROS1 INHIBITOR DOVBLERON (TALETRECTINIB ADIPATE CAPSULE)
Regulatory Filings
2025-01-03 English
INSIDE INFORMATION ANNOUNCEMENT - ENTERING INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH ROCHE FOR NOVEL DLL3 ADC
Regulatory Filings
2025-01-02 English